Scientific Posters and Presentations
Chemotherapy-Induced Nausea and Vomiting (CINV)
Hematology/Oncology Pharmacy Association Annual Meeting March 2016 - APF530: Pharmacokinetics and Efficacy of Extended-Release Granisetron Injection in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting
San Antonio Breast Cancer Symposium December 2015: Phase 3 Comparison of APF530 vs Ondansetron, Each in a Guideline-Recommended 3-Drug Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting Due to Anthracycline + Cyclophosphamide (AC)-Based Highly Emetogenic Chemotherapy (HEC) Regimens: a Post Hoc Subgroup Analysis of the MAGIC Trial
ASCO Breast Cancer Symposium September 2015: Phase 3 Study of APF530 vs Ondansetron with a Neurokinin 1 Antagonist + Corticosteroid in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: MAGIC Trial
ASCO Annual Meeting June 2014: Randomized, Double-Blind Phase 3 Trial of Extended-Release Granisetron (APF530) Versus Palonosetron for Preventing Chemotherapy-Induced Nausea and Vomiting Associated With Moderately or Highly Emetogenic Chemotherapy: Does a Reanalysis Using Newer ASCO Emetogenicity Criteria Affect Study Conclusions?
MASCC/ISOO Annual Meeting June 2012: Patient Satisfaction With Control of Emesis Following Chemotherapy: Comparison of APF530, a Subcutaneous Extended-Release Formulation of Granisetron, Versus Intravenous Palonosetron
Supportive Oncology Conference June 2009: Comparison Of Sustained Release Granisetron (APF530) To A Single Dose Of Palonosetron For The Prevention Of Chemotherapy-Induced Nausea And Vomiting (CINV) Following A Phase 3 Study